An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2016
Price : $35 *
At a glance
- Drugs Nesvacumab (Primary) ; Aflibercept
- Indications Age-related macular degeneration; Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 11 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Planned number of patients changed from 60 to 20 as per ClinicalTrials.gov record.
- 05 Apr 2015 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as per ClinicalTrials.gov record.